Polyrizon Ltd. (NASDAQ: PLRZ) has signed agreements with a single institutional investor for offerings expected to generate approximately $4.0 million in gross proceeds. The transactions cover a registered direct offering of 232,500 Ordinary Shares and 30,000 pre-funded warrants, alongside a private placement of 70,833 PIPE pre-funded warrants and 333,333 PIPE Common Warrants. The securities are priced at $12.00 per Unit, or $11.99999 per Pre-Funded Unit, and the transactions are expected to close on or about Sept. 4, 2026, subject to customary conditions. The company plans to use net proceeds and existing cash for general corporate purposes and working capital. Polyrizon develops intranasal hydrogels (nasal-delivered gels) intended to form a barrier against viruses and allergens, as well as technologies for nasal drug delivery.